Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI

Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI

(2013) Dafne D.G. Horovitz et al.   MOLECULAR GENETICS AND METABOLISM

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy

(2012) E. Braunlin et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series

(2012) Anke Thümler et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Expert recommendations for the laboratory diagnosis of MPS VI

(2012) T. Wood et al.   MOLECULAR GENETICS AND METABOLISM

Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)

(2011) Christian J. Hendriksz et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI

(2011) Mahoko Furujo et al.   MOLECULAR GENETICS AND METABOLISM

Mucopolysaccharidosis VI

(2010) Vassili Valayannopoulos et al.   Orphanet Journal of Rare Diseases

Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study

(2009) JJ McGill et al.   CLINICAL GENETICS

Growth charts for patients affected with Morquio A disease

(2008) Adriana M. Montaño et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

(2008) Paul Harmatz et al.   MOLECULAR GENETICS AND METABOLISM